# A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib

Source: https://onco.cc/trials/nct07362940/  
OnCo record `nct07362940` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of GEN-725 tablets + Dositinib mesylate tablets in non-small-cell lung cancer, run by Henan Genuine Biotech Co., Ltd., now recruiting.

## Summary

A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib is a phase 1/2 interventional study registered as NCT07362940 by Henan Genuine Biotech Co., Ltd., with 110 participants planned, started 2025-11-27 and due to reach its primary completion in 2027-07-31. Interventions recorded: GEN-725 tablets + Dositinib mesylate tablets.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07362940
- Phase: 1/2
- Setting: A Phase Ⅰ/Ⅱa Clinical Study Evaluating the Efficacy and Safety of GEN-725 in Combination With Dositinib in Patients With Locally Advanced or Metastatic EGFR-Mutant Non-small Cell Lung Cancer
- Sponsor: Henan Genuine Biotech Co., Ltd.
- Enrolled: 110

## Sources

- ClinicalTrials.gov NCT07362940: https://clinicaltrials.gov/study/NCT07362940

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [Henan Genuine Biotech](https://onco.cc/companies/henan-genuine-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct07362940.json